Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Endogenous IFNλ in viral hepatitis patients.
de Groen RA, Mcphee F, Friborg J, Janssen HL, Boonstra A. de Groen RA, et al. Among authors: mcphee f. J Interferon Cytokine Res. 2014 Jul;34(7):552-6. doi: 10.1089/jir.2013.0068. Epub 2014 Jan 16. J Interferon Cytokine Res. 2014. PMID: 24433037
Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir.
McPhee F, Friborg J, Levine S, Chen C, Falk P, Yu F, Hernandez D, Lee MS, Chaniewski S, Sheaffer AK, Pasquinelli C. McPhee F, et al. Antimicrob Agents Chemother. 2012 Jul;56(7):3670-81. doi: 10.1128/AAC.00308-12. Epub 2012 Apr 16. Antimicrob Agents Chemother. 2012. PMID: 22508297 Free PMC article. Clinical Trial.
Pegylated interferons Lambda-1a and alfa-2a display different gene induction and cytokine and chemokine release profiles in whole blood, human hepatocytes and peripheral blood mononuclear cells.
Freeman J, Baglino S, Friborg J, Kraft Z, Gray T, Hill M, McPhee F, Hillson J, Lopez-Talavera JC, Wind-Rotolo M. Freeman J, et al. Among authors: mcphee f. J Viral Hepat. 2014 Jun;21(6):e1-9. doi: 10.1111/jvh.12243. J Viral Hepat. 2014. PMID: 24827902 Clinical Trial.
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).
McPhee F, Sheaffer AK, Friborg J, Hernandez D, Falk P, Zhai G, Levine S, Chaniewski S, Yu F, Barry D, Chen C, Lee MS, Mosure K, Sun LQ, Sinz M, Meanwell NA, Colonno RJ, Knipe J, Scola P. McPhee F, et al. Antimicrob Agents Chemother. 2012 Oct;56(10):5387-96. doi: 10.1128/AAC.01186-12. Epub 2012 Aug 6. Antimicrob Agents Chemother. 2012. PMID: 22869577 Free PMC article.
The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection.
Scola PM, Sun LQ, Wang AX, Chen J, Sin N, Venables BL, Sit SY, Chen Y, Cocuzza A, Bilder DM, D'Andrea SV, Zheng B, Hewawasam P, Tu Y, Friborg J, Falk P, Hernandez D, Levine S, Chen C, Yu F, Sheaffer AK, Zhai G, Barry D, Knipe JO, Han YH, Schartman R, Donoso M, Mosure K, Sinz MW, Zvyaga T, Good AC, Rajamani R, Kish K, Tredup J, Klei HE, Gao Q, Mueller L, Colonno RJ, Grasela DM, Adams SP, Loy J, Levesque PC, Sun H, Shi H, Sun L, Warner W, Li D, Zhu J, Meanwell NA, McPhee F. Scola PM, et al. Among authors: mcphee f. J Med Chem. 2014 Mar 13;57(5):1730-52. doi: 10.1021/jm500297k. Epub 2014 Mar 5. J Med Chem. 2014. PMID: 24564672
105 results